All News

RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
injection-green.jpg

Anakinra's Effects on COVID-19 Outcomes

Jack Cush, MD

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote

Read Article
RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
2020 Year Review

ICYMI: 2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
colonperf.png

Tocilizumab Risk of Diverticulitis and GI Perforation

Jack Cush, MD

A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA

Read Article
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed. https://t.co/UpQjFgKTpE https://t.co/3dQ2jacwJD

Links:

Dr. John Cush RheumNow ( View Tweet)
New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
These companies do auto-inflammatory gene testing in the USA. @RWCSmtg https://t.co/89bWd0SiAI
Dr. John Cush RheumNow ( View Tweet)
Video: What Kind of Diet Should You be on? with Dr. Robert Chao ( @doctorRBC) https://t.co/jqkA8vrgww #EULAR2021 https://t.co/5mPuZWmw20

Links:

Dr. John Cush RheumNow ( View Tweet)
We need to revisit #SLEDAI #lupus arthritis. Drs Mahmoud & Vital reported only 48% without swelling had MSK-US synovitis; 90% with swelling. They proposed new TERM: Inflammatory joint pain with =>2 SJC. Need to get this right as it impacts SRI-4 #EULAR2021 #POS0746 @RheumNow https://t.co/JPqOMLQ2ES
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Apremilast in Behcet’s - RELIEF European subgroup analysis ⬇️oral ulcer count, ulcer pain, disease activity ⬆️QoL ⭐️results consistent with general population Abs#POS0254 #EULAR2021 @RheumNow https://t.co/NVGt4TjkYY
Robert B Chao, MD doctorRBC ( View Tweet)
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein ejdein1 ( View Tweet)

#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao KDAO2011 ( View Tweet)
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)
Virtual DDW meeting this wk reports claims data comparing IBD to IBD with RA - IBD alone vs IBD w/ RA dx w/ more depression (21% vs 84%), anxiety (20% vs 47%). IBD w/ RA had more depression (OR 7.2); anxiety (OR, 1.25;) or both (OR, 2.3) https://t.co/B78xcJw584

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Checkpoint Inhibitor Safety in Melanoma Patients with AID A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD. https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×